Revenue Breakdown
Composition ()
No data
Revenue Streams
X T L Biopharmaceuticals Ltd (XTLB) generates its revenue primarily from Operating Segment / Medical Devices, which accounts for -205.2% of total sales, equivalent to $-589.00K. Understanding this concentration is critical for investors evaluating how XTLB navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, X T L Biopharmaceuticals Ltd maintains a gross margin of -436.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3005.03%, while the net margin is -1063.83%. These profitability ratios, combined with a Return on Equity (ROE) of -577.13%, provide a clear picture of how effectively XTLB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, XTLB competes directly with industry leaders such as IINN and IRIX. With a market capitalization of $10.12M, it holds a significant position in the sector. When comparing efficiency, XTLB's gross margin of -436.56% stands against IINN's 0.69% and IRIX's 32.15%. Such benchmarking helps identify whether X T L Biopharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.
